World Sleep Industry ENCYCLOPEDIA

Magnesium Glycinate

3.1.1

Compound identity and naming boundaries

Magnesium glycinate is a salt or coordination compound of magnesium and glycinate. A defined magnesium bisglycinate is commonly represented by one Mg²⁺ ion and two glycinate anions. Magnesium glycinate, magnesium bisglycinate, and magnesium diglycinate therefore often point to a similar identity in commerce, but a marketing term does not always prove an identical hydration state, degree of coordination, or purity. Identity should be established from the full chemical name, specification, elemental-magnesium fraction, and lot testing.

This entry concerns a supplement whose principal active ingredient is magnesium glycinate under WSIC 3.1.1. It is different from free glycine, a simple mixture of glycine with another magnesium salt, and magnesium oxide, citrate, L-threonate, taurate, or a multi-salt magnesium blend. “Chelated” on a label does not automatically prove that all magnesium has the same coordination structure. “Buffered” may indicate that the formulation also contains magnesium oxide or another source and calls for review of the full ingredient list and raw-material specification.

Glycine has no chiral center, so “L-magnesium glycinate” does not normally describe another, more active enantiomer. In the gastrointestinal environment, the compound can dissociate to varying degrees, and subsequent absorption and distribution depend on amount, meals, intestinal condition, magnesium status, and formulation. Even if some material is absorbed in a coordinated form, amino-acid chelation alone cannot prove that it never causes diarrhea, is completely absorbed, enters the brain, or outperforms every other magnesium salt.

Elemental magnesium, glycine, and interpretation of absorption

“2,000 mg magnesium glycinate” on the front of a label ordinarily refers to the mass of the compound or raw material, not 2,000 milligrams of elemental magnesium. The theoretical elemental-magnesium fraction of ideal anhydrous magnesium bisglycinate is approximately 14%; a hydrate or blended material can be lower or different. Calculations should use the elemental-magnesium amount explicitly stated in the supplement facts. An unusually high elemental percentage from a small stated compound mass warrants checking for buffering, added magnesium salts, and consistent labeling bases.

Magnesium bisglycinate supplies both magnesium and a glycine moiety, but whole-compound mass, elemental magnesium, and an equivalent amount of free glycine are not one measure. The direct 2025 sleep trial supplied 250 milligrams of elemental magnesium and about 1.523 grams of glycine moiety daily. It did not include an equal-elemental-magnesium arm using another salt, an equal amount of free glycine, or a factorial comparison, so the small result cannot be assigned to magnesium, glycine, coordination form, or their combination.

An early isotope crossover study in only 12 patients after ileal resection found similar overall absorption of magnesium diglycinate and oxide. Chelate absorption was higher among the four patients with the poorest oxide absorption, and tolerance was reported as better. A small result in this unusual intestinal population does not establish the same advantage for healthy consumers. A one-day change in blood or urine also does not establish long-term tissue utilization, clinical benefit, or improved sleep.

Sleep research and evidentiary limits

A 2025 double-blind placebo-controlled trial enrolled 155 generally healthy adults aged 18 to 65 who reported poor sleep and compared magnesium bisglycinate providing 250 milligrams of elemental magnesium daily with placebo for four weeks. Mean Insomnia Severity Index improvements were approximately 3.9 points and 2.3 points, respectively. The adjusted between-group difference only just reached statistical significance, and the effect size was small. The average post-intervention score remained in the subthreshold-insomnia range, so the result cannot be presented as elimination of insomnia for most users.

The trial used online self-report questionnaires without actigraphy, electroencephalography, or polysomnography. Other sleep, fatigue, daytime sleepiness, stress, and mood measures did not differ significantly between groups. A suggestion of larger response among people with lower dietary magnesium came from a single unvalidated dietary question and was exploratory. Four weeks, one product, a predominantly female sample, and exclusion of many illnesses and medicines also limit extension to long-term use, diagnosed chronic insomnia, and medically complex patients.

A 2026 systematic review of randomized oral-magnesium sleep trials in adults combined multiple magnesium forms and found inconsistent results across subjective measures, electroencephalography, research-grade actigraphy, and consumer devices. Certainty was low to very low, and routine oral magnesium treatment for insomnia was not supported. One direct bisglycinate trial offers an initial small-effect signal but cannot determine an optimal population, amount, or duration. It cannot replace cognitive behavioral therapy for insomnia or treat sleep apnea, circadian disorders, or another cause of poor sleep.

Dosage forms, labeling, and quality control

Magnesium glycinate is sold as capsules, tablets, powders, gummies, and blends. Label review should record elemental magnesium per serving, total magnesium-glycinate raw material, units per serving, daily servings, and every other magnesium source. Supplemental elemental magnesium from multivitamin-minerals, antacids, laxatives, and electrolyte drinks should be added. High absorption, gentle, fully chelated, and unbuffered should be supported by a verifiable specification rather than a front-label icon.

Raw-material and finished-product control should address the molar ratio of magnesium to glycinate, elemental magnesium and glycine assay, hydration state, free glycine, unreacted starting material, magnesium oxide or another buffering salt, inorganic impurities, residual solvents, heavy metals, microorganisms, dosage uniformity, and shelf-life stability. Identity may require suitable spectroscopy, chromatography, or other methods combined with assay. Measuring total magnesium alone cannot prove that magnesium is present in the claimed bisglycinate structure.

European regulatory material has found magnesium bisglycinate meeting the evaluated specification not to raise safety concerns as a magnesium source for food supplements. Such a conclusion applies to a defined identity and conditions of use and is not approval of sleep efficacy. Naming practices, disclosure of buffering materials, elemental-magnesium limits, and health-claim rules differ among jurisdictions. Cross-market comparison should return to the actual formulation, finished-product lot, and local label rather than assuming that the same generic name always denotes the same raw material.

Use records and review of outcomes

Before a self-directed trial, the target should be defined as perceived difficulty falling asleep, nighttime wakefulness, inadequate sleep opportunity, or next-day function, and every magnesium-containing medicine and supplement should be listed. Changing one factor at a time while keeping caffeine, alcohol, exercise, light exposure, and schedule reasonably stable improves interpretability. A person should not stop medicine because a product contains both magnesium and glycine or add several magnesium salts, free glycine, melatonin, and sedating herbs on the same night.

A useful record can include brand and lot, whether the label says bisglycinate or buffered, elemental magnesium and whole-compound mass per serving, actual capsules or scoop, timing, spacing from meals and medicines, all supplemental magnesium that day, bedtime and rise time, estimated sleep onset, awakenings, next-day alertness, bowel changes, and other adverse effects. Trends across several nights and daytime function matter more than a single dream or wearable score and should not prompt temporary dose escalation.

Diarrhea, nausea, abdominal pain, dizziness, weakness, sleepiness, muscle weakness, palpitations, or worse sleep should prompt an end to unsupervised escalation and a fresh check of total elemental magnesium, kidney function, and the complete formulation. If the target is not met, increasing compound grams, stacking other magnesium salts, or adding more glycine makes benefits and symptoms harder to attribute. Persistent insomnia, substantial daytime impairment, snoring with gasping, or abnormal sleepiness requires evaluation of the cause.

Safety, interactions, and special populations

Healthy kidneys usually remove excess magnesium, but too much from supplements or magnesium-containing medicines can cause diarrhea, nausea, and abdominal cramping. Very high exposure can cause hypotension, slowed responsiveness, muscle weakness, difficulty breathing, abnormal heart rhythm, and cardiac arrest. Reduced kidney function markedly increases hypermagnesemia risk. “Gentle on the stomach” is a relative tolerance claim, not a guarantee that an individual will have no symptoms, and it does not exclude a reaction to excipients or other blend ingredients.

Magnesium can form complexes with tetracycline and quinolone antibiotics and reduce absorption of oral bisphosphonates. Exact spacing should follow the medicine label or advice from a physician or pharmacist. Diuretics can increase or decrease urinary magnesium loss, while long-term proton-pump inhibitor use can cause low magnesium. A chelating ligand does not remove these elemental-magnesium interactions, and antacids, laxatives, and other mineral formulas must be included in total exposure.

The four-week trial in healthy adults should not be copied directly to kidney disease, cardiac conduction problems, hypotension, gastrointestinal disease, complex chronic illness, pregnancy, breastfeeding, childhood, surgery, or anesthesia. Severe weakness, fainting, slowed responsiveness, difficulty breathing, persistent vomiting or diarrhea, marked hypotension, or a rhythm disturbance requires prompt care. After an overdose, a child’s accidental ingestion, or concurrent use of a large amount of magnesium-containing medicine, a person should not wait for an ordinary laxative effect to end on its own.

Procurement, claims, and related entries

For personal selection, useful features include a clear elemental-magnesium amount, total magnesium glycinate, magnesium-to-glycine ratio, buffering salts, and all excipients, plus an identifiable responsible business, lot, expiry, and lot-specific testing. Institutional procurement should additionally review the raw-material supplier, chelation and blending process, identity and assay methods, stability, change control, complaints, adverse events, and recall procedures. A high price, patent, imported status, or “100% chelated” slogan cannot replace finished-product evidence.

Amino-acid chelate, high bioavailability, and less diarrhea should identify the comparator, equal-elemental-magnesium condition, population, and endpoint. A small ileal-resection study does not prove superiority to oxide for every healthy person, and one four-week self-report trial does not prove increased deep sleep, relief of anxiety, or treatment of chronic insomnia. Magnesium participates in neural function and glycine in neurotransmission, but adding those mechanisms does not create proven synergistic hypnotic action.

Related entries include glycine, magnesium nutrition and deficiency, magnesium oxide, citrate, L-threonate, and taurate, magnesium-containing antacids and laxatives, and cognitive behavioral therapy for insomnia. Relatedness does not make interchange or stacking appropriate. Assessment of any product should return to elemental magnesium, actual salt form, glycine moiety, kidney function, concurrent medicines, intended goal, and verifiable outcomes.